Mouse CD27/TNFRSF7 Antibody (137910)

Detection of Mouse CD27/TNFRSF7 by Western Blot.

Western blot shows lysates of mouse spleen tissue. PVDF Membrane was probed with 2 µg/mL of Mouse CD27/TNFRSF7 Monoclonal Antibody (Catalog # MAB574) followed by HRP-conjugated Anti-Rat IgG Secondary Antibody (Catalog # HAF005). A specific band was detected for CD27/TNFRSF7 at approximately 45 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 7.

CD27/TNFRSF7 in Mouse Splenocytes.

CD27/TNFRSF7 was detected in immersion fixed mouse splenocytes using Rat Anti-Mouse CD27/TNFRSF7 Monoclonal Antibody (Catalog # MAB574) at 8 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Rat IgG Secondary Antibody (red; Catalog # NL013) and counterstained with DAPI (blue). Specific staining was localized to plasma membrane. View our protocol for Fluorescent ICC Staining of Non-adherent Cells.

Detection of CD27/TNFRSF7 by Western Blot

KMT9 is expressed in lung cancer tissue and cell lines. a Dynamics of KMT9 alpha expression in matched normal and stage 1a lung adenocarcinoma tissue from eleven patients that underwent curative lobectomy. Normal samples were taken at 6 cm distance from macroscopic tumor sites. Data were extracted from (GSE83213). Red lines indicate increased expression of KMT9 alpha in tumor (n = 8), green lines indicate decreased expression of KMT9 alpha in tumor (n = 3). b TCGA data comparing KMT9 alpha expression in n = 515 lung adenocarcinoma with non-matched normal lung tissue (n = 59). Data represent interquartile range including minimum, 25th percentile, median, 75th percentile and maximum values. Significance was accessed by t test. c Kaplan–Meier survival analysis of patients with adenocarcinoma expressing high (n = 58) and low (n = 57) KMT9 alpha. Data were extracted from GSE26939. HR = hazard ratio. d Western blots of matched tissue from normal and tumor samples from patients with adenocarcinoma (#1 and #2) or SCLC (#3 and #4). Western blots were performed with the indicated antibodies. e Expression levels of KMT9 alpha and KMT9 beta in human cell lines from SCLC (GLC-2 and NCI-H82), adenocarcinoma (A549, PC-9 and NCI-H2087) and human immortalized normal lung fibroblasts (CRL-7000 and IMR-90) were analyzed by western blot using the indicated antibodies. f In A549 cells, KMT9 alpha and KMT9 beta are present in both nuclear and cytoplasmic compartments. Western blots were performed with the indicated antibodies. g Levels of H4K12me1 in SCLC (GLC-2 and NCI-H82) and adenocarcinoma (A549, PC-9 and NCI-H2087) cells were analyzed by western blotting using the indicated antibodies Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/32095117), licensed under a CC-BY license. Not internally tested by R&D Systems.